bearish
An activist tried to take on Pfizer. Then things got messy
SUMMARY
- Pfizer CEO Albert Borla receives a strange email from the company's former CFO Frank D'Amelio, signaling the beginning of a chaotic activist investor campaign
- Pfizer's success with the Covid-19 vaccine leads to record highs in market cap, but challenges arise as the vaccine becomes old news and competitors emerge in the weight loss drug sector
- Pfizer's acquisition of cancer drug maker CGenta for $43 billion is criticized by investors, leading to a collapse in the company's share price and making it a prime target for an activist investor
This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
x